Bioheart, Inc. Announces Additional Funding Support

SUNRISE, Fla., Oct. 17, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc., (Nasdaq:BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced it has received an aggregate of approximately $1.8 million in cash from accredited investors, including existing shareholders. Between October 1, 2008 and October 10, 2008, the Company sold, in a private placement, an aggregate of 1,003,910 shares of the Company's common stock and warrants to purchase 301,173 shares of the Company's common stock. The warrants are exercisable solely for cash at a weighted average exercise price of $2.12 per share during the period commencing on the date that is six months and one day following the date of issuance and ending on the third year anniversary of the date of issuance.